Evidence map›Paper›PMID 41648453›Full record

ArticlebioRxiv : the preprint server for biology2026

Akanksha Varshney, Ziyi Jia, Gebremichal Gebretsadik, Narendran G-Dayanandan, Terry L Bowlin, Michelle M Butler, Anthony D Baughn, Kenneth C Keiler

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Updated by
    2026
5 · Who and what money

Authors and funding

8 authors.

Akanksha VarshneyDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712 USA.
Ziyi JiaDepartment of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455 USA.
Gebremichal GebretsadikDepartment of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455 USA.
Narendran G-DayanandanMicrobiotix, Inc., Worcester, MA 01605 USA.
Terry L BowlinMicrobiotix, Inc., Worcester, MA 01605 USA.
Michelle M ButlerMicrobiotix, Inc., Worcester, MA 01605 USA.
Anthony D BaughnDepartment of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455 USA.
Kenneth C KeilerDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712 USA.

Funding

Targeting trans-translation to kill M. tuberculosis non-replicating persister cellsR01AI158706 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI ANTHONY D BAUGHN, Kenneth C Keiler · 2022 to 2026
$3.4M
NIAID NIH HHS R01 AI158706
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acylaminooxadiazoleantibiotic resistancemetal homeostasisMycobacterium abscessusMycobacterium aviumMycobacterium tuberculosistrans-translation

Identifiers

PMID41648453
PMCPMC12871676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.